Cargando…
Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable
There is growing interest in regulatory use of randomized pragmatic trials and noninterventional real-world (RW) studies of effectiveness and safety, but there is no agreed-on framework for assessing when this type of evidence is sufficiently reliable. Rather than impose a clinical trial–like paradi...
Autor principal: | Dreyer, Nancy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944086/ https://www.ncbi.nlm.nih.gov/pubmed/29714575 http://dx.doi.org/10.1177/2168479018763591 |
Ejemplares similares
-
4505 Implementation of Real-World Data and Real-World Evidence in Clinical Studies
por: Pham, Jessica, et al.
Publicado: (2020) -
Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010) -
4349 Survey of Regulatory Reforms to Address Comprehension of Clinical Trial Results
por: Kirkland, Matthieu, et al.
Publicado: (2020) -
Regulatory requirements for marketing fixed dose combinations
por: Jayasheel, B. G.
Publicado: (2010) -
Drug Lag and Key Regulatory Barriers in the Emerging Markets
por: Wileman, Harriet, et al.
Publicado: (2010)